Introduction to the background, principles, and state of the art in suicide gene therapy

Molecular Biotechnology

Volumn 30, Issue 1, 2005, Pages 71-88

  Niculescu Duvaz, Ion ^a   Springer, Caroline J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Bystander effect; Enzymes for GDEPT; GDEPT; Imaging; Prodrugs; Suicide gene therapy

Indexed keywords

CELLS; DRUG PRODUCTS; ENZYMES; IMAGING TECHNIQUES; IMMUNOLOGY; TUMORS;

BYSTANDER EFFECT; ENZYMES FOR GDEPT; GDEPT; PRODRUGS; SUICIDE GENE THERAPY;

GENETIC ENGINEERING;

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; 5 (2 BROMOVINYL) 2' DEOXYURIDINE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 HYDROXYSTAUROSPORINE; ACICLOVIR; ANTHRACYCLINE ANTIBIOTIC AGENT; BROXURIDINE; BUTYRIC ACID; CAMPTOTHECIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 1A2; CYTOCHROME P450 2B1; CYTOCHROME P450 2B6; DITERPENOID; FLUOROURACIL; GANCICLOVIR; HORSERADISH PEROXIDASE; HYDROXYUREA; INDOLEACETIC ACID; IRINOTECAN; N [4 [(2 CHLOROETHYL)(2 MESYLOXYETHYL)AMINO]BENZOYL]GLUTAMIC ACID; PACLITAXEL; PARACETAMOL; PENCICLOVIR; PONICIDIN; SORIVUDINE; TAXOID; THIAMAZOLE; THYMIDINE KINASE; TIRAPAZAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; URACIL PHOSPHORIBOSYLTRANSFERASE; ZD 2767 P;

BONE MARROW TOXICITY; BYSTANDER EFFECT; CANCER CHEMOTHERAPY; CELL COMPOSITION; COLON CARCINOMA; DNA MODIFICATION; DNA TRANSFECTION; DRUG SAFETY; DRUG SELECTIVITY; EXPRESSION VECTOR; GENE DELIVERY SYSTEM; GENE TECHNOLOGY; GLIOMA; HUMAN; IMMUNE RESPONSE; NONHUMAN; REVIEW; SITE DIRECTED MUTAGENESIS; SUICIDE GENE THERAPY; THEORETICAL STUDY;

EID: 25444474137     PISSN: 10736085     EISSN: None     Source Type: Journal    
DOI: 10.1385/mb:30:1:071     Document Type: Review

References (89)

1. Marais, R., Spooner, R. A., Light, Y., Martin, J., and Springer, C. J. (1996) Gene-directed enzyme prodrug therapy with a mustard prodrug/ carboxypeptidase G2 combination. Cancer Res. 56, 4735-4742.
2. Bridgewater, G., Springer, C. J., Knox, R., Minton, N., Michael, P., and Collins, M. (1995) Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur. J. Cancer 31A, 2362-2370.
3. Huber, B. E., Richards, C. A., and Austin, E. A. (1995) VDEPT; an enzyme/prodrug gene therapy approach for the treatment of metastatic colorectal cancer. Adv. Drug Delivery Rev. 17, 279-292.
4. Eaton, J. L., Perry, M. J. A., Todryk, S. M., et al. (2001) Genetic prodrug activation therapy (GPAT) in two rat prostate models generates an immune bystander effect and can be monitored by magnetic resonance techniques. Gene Ther. 8, 557-567.
5. Hermiston, T. (2000) Gene-delivery from replication-selective viruses: arming guided missiles in the war against cancer. J. Clin. Invest. 105, 1169-1172.
6. Roth, J. A. and Cristiano, R. G. (1997) Gene therapy for cancer: what have we done and where are we going? J. Natl. Cancer Inst. 89, 21-30.
7. Niculescu-Duvaz, I., Spooner, R., Marais, R., and Springer, C. J. (1998) Gene-directed enzyme prodrug therapy. Bioconj. Chem. 9, 4-22.
8. Springer, C. J. and Niculescu-Duvaz, I. (1999) Patent property of prodrug involving gene therapy (1996-1999). Exp. Opin. Ther. Patents 9, 1381-1388.
9. Bilbao, G., Contreras, J. L., Gómez-Navarro, J., and Curiel, D. T. (1998) Improving adenoviral vectors for cancer gene therapy. Tumor Target. 3, 59-79.
10. Nguyen, J. T., Wu, P., Clouse, M. E., Hlatky, L., and Terwilliger, E. F. (1998) Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor stratergy. Cancer Res. 58, 5673-5677.
11. Robbins, P. D. and Ghivizzani, S. C. (1998) Viral vectors for gene therapy. Pharm. Ther. 80, 35-47.
12. Zhang, W. W. (1999) Development and application of adenoviral vectors for gene therapy of cancer. Cancer Gene Ther. 7, 113-138.
13. Curiel, D. T., Gerritsen, W. R. and Krul, M. R. (2000) Progress in cancer gene therapy. Cancer Gene Ther. 7, 1197-1199.
14. Roth, M. G. and Curiel, D. T. (2000) Toward the optimal vector for prostate cancer gene therapy; a CaPCURE meeting report. Cancer Gene Ther. 7, 1507-1510.
15. Kirn, D. (2001) Clinical research results with dI 1520 (ONYX-015), a replication selective adenovirus for the treatment of cancer: what have we learned? Gene Ther. 8, 89-98.
16. Miller, A. D. (1998) Cationic liposomes for gene therapy. Angew. Chem. Int. Ed. 37, 1768-1785.
17. Schatzlein, A. G. (2001) Non-viral vectors in cancer gene therapy: principles and progress. Anti-Cancer Drug Des. 12, 275-304.
18. Springer, C. J. and Niculescu-Duvaz, I. (2000) Prodrug-activating systems in suicide gene therapy. J. Clin. Investig. 105, 1161-1167.
19. Encell, L. P., Landis, D. M. and Loeb, L. A. (1999) Improving enzymes for gene therapy. Nature Biotechnol. 17, 143-147.
20. Mesnil, M. and Yamasachi, H. (2000) Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communications. Cancer Res. 60, 3989-3999.
21. Denny, W. A. and Wilson, W. R. (1998) The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme prodrugs therapies. J. Pharm. Pharmacol. 50, 387-394.
22. Niculescu-Duvaz, I., Friedlos, F., Niculescu-Duvaz, D., Davies, L., and Springer, C. J. (1999) Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT). Anticancer Drug Des. 14, 517-538.
23. Springer, C. J. and Niculescu-Duvaz, I. (2002) Gene-directed enzyme prodrug therapy. In: Anticancer Drug Development (Baguley, B., ed.). Academic, New York, pp. 137-135.
24. Marais, R., Spooner, R. A., Stribbling, S. M., Light, Y., Martin, J., and Springer, C. J. (1997) A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy. Nature Biotechnol. 15, 1373-1377.
25. Loimas, S., Toppinen, M.-R., Visakorpi, T., Janne, J., and Wahlfors, D. (2001) Human prostate carcinoma cells as target for herpes simplex virus thymidine kinase-mediated suicide gene therapy. Cancer Gene Ther. 8, 137-144.
26. Jones, R. K., Pope, I. M., Kinsella, A. R., Watson, A. J. M., and Christmas, S. E. (2000) Combined suicide and granulocyte-macrophage colony-stimulating factor gene therapy induces complete tumor regression and generates antitumor immunity. Cancer Gene Ther. 7, 1519-1528.
27. Walling, H. W., Swarthout, G. T., and Culver, K. W. (2000) Bystander-mediated regression of osteosarcoma via retroviral transfer of the herpes simplex virus thymidine kinase and human interleukin-2 genes. Cancer Gene Ther. 7, 187-196.
28. Howard, B. D., Boenicke, L., Schniewind, B., Henne-Bruns, D., and Kalthoff, H. (2000) Transduction of human pancreatic tumor cells with vesicular stomatitis virus G-pseudotyped retroviral vectors containing a herpes simplex virus thymidine kinase mutant gene enhances bystander effects and sensitivity to ganciclovir. Cancer Gene Ther. 7, 927-938.
29. Sandmair, A.-M., Turunen, M., Tyynela, K., et al. (2000) Herpes simplex virus thymidine kinase gene therapy in experimental rat BT4C glioma model: effect of the percentage of thymidine kinase-positive glioma cells on treatment effect, survival time, and tissue reac­tions. Cancer Gene Ther. 7, 413-421.
30. Kruse, C. A., Lamb, C., Hogan, S., Russell Smiley, W., Kleinschmidt-DeMasters, B., and Burrows, F. G. (2000) Purified herpes simplex thymidine kinase retroviral particles. II. Influence of clinical parameters and bystander killing mechanisms. Cancer Gene Ther. 7, 118-127.
31. Hamel, W., Zirkel, D., Mehdorn, H. M., Westphal, M., and Israel, M. A. (2001) E-5-(2-bromovinyl)-2′-deoxyuridine potentiates ganciclovir-mediated cytotoxicity on herpes simplex virus-thymidine kinase-expressing cells. Cancer Gene Ther. 8, 388-396.
32. Grignet-Debrus, C., Cool, V., Baudson, N., et al. (2000) Comparative in vitro and in vivo cytotoxic activity of (E)-5-(2-bromovinyl)-2′- deoxyuridine (BVDU) and its arabinosyl derivative, (E)-5-(2-bromovinyl)-1- β-D-arabinofuranosyluracil (BVaraU), against tumor cells expressing either the Varicella zoster or the Herpes simplex virus thymidine kinase. Cancer Gene Ther. 7, 215-223.
33. Erbs, P., Regulier, E., Kintz, J., et al. (2000) In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res. 60, 3813-3822.
34. Bentires-Alj, M., Helin, A.-C., Lechanteur, C., et al. (2000) Cytosine deaminase suicide gene therapy for peritoneal carcinomatosis. Cancer Gene Ther. 7, 20-26.
35. Spooner, R. A., Maycroft, K. A., Paterson, H., Friedlos, F., Springer, C. J., and Marais, R. (2001) Appropriate subcellular location of prodrug-activating enzymes has important consequences for suicide gene therapy. Int. J. Cancer 93, 123-130.
36. Westphal, E.-M., Ge, J., Catchpole, J. R., Ford, M., and Kennedy, S. C. (2000) The nitroreductase/CB1954 combination in Epstein-Barr virus-positive B cell lines: induction of bystander killing in vitro and in vivo. Cancer Gene Ther. 7, 97-106.
37. Tatcher, N. J., Edwards, R. J., Lemoine, N. R., Doehmer, J., and Davies, D. S. (2000) The potential of acetaminophen as a prodrug in gene-directed enzyme therapy. Cancer Gene Ther. 7, 521-525.
38. Heine, D., Muller, R., and Brusselbach, S. (2001) Cell surface display of a lysosomal enzyme for extra-cellular gene-directed enzyme prodrug therapy. Gene Ther. 8, 1005-1010.
39. Hamstra, D. A., Page, M., Maybaum, J., and Rehemtulla, A. (2000) Expression of endogenously activated secreted or cell surface carboxypeptidase A sensitizes tumor cells to methotrexate-_-peptide prodrugs. Cancer Res. 60, 657-665.
40. Stribbling, S. M., Friedlos, F., Martin, J., et al. (2000) Regressions of established breast cancer xenografts by carboxypeptidase G2 suicide gene therapy and the prodrug CMDA are due to a bystander effect. Hum. Gene Ther. 11, 285-292.
41. Greco, O., Folkes, L. K., Wardman, P., Tozer, G. M., and Dachs, G. U. (2000) Development of a novel enzyme/prodrug combination for gene therapy of cancer: horseradish per-oxidase/indole-3-acetic acid. Cancer Gene Ther. 7, 1414-1420.
42. Simonova, M., Wall, A., Weissleder, R., and Bogdanov, A. (2000). Tyrosinase mutants are capable of prodrug activation in transfected non-melanotic cells. Cancer Res. 60, 6656-6662.
43. Kawamura, K., Tasaki, K., Hamada, H., Takenaga, K., Sakiyama, S., and Tagawa, M. (2000) Expression of Escherichia coli uracil phosphoribosyltransferase gene in murine colon carcinoma cells augments the antitumoral effect of 5-fluorouracil and induces protective immunity. Cancer Gene Ther. 7, 637-643.
44. Cuq, P., Rouquet, C., Evrard, A., Ciccolini, J., Vian, L., and Cano, J.-P. (2001) Fluoropyrimidine sensitivity of human MCF-7 breast cancer cells stably transfected with human uridine phosphorylase. Br. J. Cancer 84, 1677-1680.
45. Weyel, D., Sedlacek, H. H., Muller, R., and Brusselbach, S. (2000) Secreted human _-glucuronidase: a novel tool for gene-directed enzyme prodrug therapy. Gene Ther. 7, 224-231.
46. Black, M. E., Newcomb, T. G., Wilson, H. M., and Loeb, L. A. (1996) Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy. Proc. Natl. Acad. Sci. USA 93, 3525-3529.
47. Black, M., Kokoris, M. S., and Sabo, P. (2001) Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing. Cancer Res. 61, 3022-3026.
48. Blanche, F., Cameron, B., Couder, M., and Crouzet, J. (1997). Enzymes Combinations for Destroying Proliferative Cells, US Patent W09735024, Rhone-Poulenc Roerer, p. 1-61.
49. Chen, L., Yu, L. J., and Waxman, D. J. (1997) Potentiation of cytochrome P450/cyclo-phosphamide-based cancer gene therapy by coexpression of the P450 reductase gene. Cancer Res. 57, 4830-4837.
50. Kim, Y. G., Bi, W., Feliciano, E. S., Drake, R. R., and Stambrook, P. J. (2000) Ganciclovir-mediated cell killing and bystander effect is enhanced in cells with two copies of the herpes simplex virus thymidine kinase. Cancer Gene Ther. 7, 240-246.
51. Kammertoens, T., Gelbmann, W., Karle, P., et al. (2000) Combined chemotherapy of murine mammary tumors by local activation of the prodrug ifosfamide and 5-fluorocytosine. Cancer Gene Ther. 7, 629-636.
52. Rogulski, K. R., Wing, M. S., Paielli, D. L., Gilbert, J. D., Kim J. H., and Freytag, S. O. (2000) Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization. Hum. Gene Ther. 11, 67-76.
53. Toda, M., Martuza, R. L., and Rabkin, S. D. (2001) Combination suicide/cytokine gene therapy as adjuvants to a defective herpes simplex virus-based cancer vaccine. Gene Ther. 8, 332-339.
54. Candotti, F., Agbaria, R., Mullen, C. A., et al. (2000) Use of a herpes thymidine kinase/neomycin phosphotransferase chimeric gene for metabolic suicide gene therapy. Cancer Gene Ther. 7, 574-580.
55. Thust, R., Tomicic, M., Klocking, R., Voutilainen, N., Wutzler, P., and Kaina, B. (2000) Comparison of the genotoxic and apoptosis-inducing properties of ganciclovir and penciclovir in Chinese hamster ovary cells transfected with the thymidine kinase gene of herpes simplex virus-1: implication for gene therapeutic approaches. Cancer Gene Ther. 7, 107-117.
56. Hasegawa, Y., Nishiyama, Y., Imaizumi, K., et al. (2000) Avoidance of bone marrow suppression using A-5021 as a nucleoside analog for retrovirus-mediated herpes simplex virus type I thymidine kinase gene therapy. Cancer Gene Ther. 7, 557-562.
57. Hayashi, K., Hayashi, T., Sun, H.-D., and Takeda, I. (2000) Potentiation of ganciclovir toxicity in the herpes simplex virus thymidine kinase/ganciclovir administration system by ponicidin. Cancer Gene Ther. 7, 45-42.
58. McMasters, R. A., Wilbert, T. N., Jones, K. E., et al. (2000) Two-drug combinations that increase apoptosis and modulate Bak and Bcl-XL expression in human colon tumor cell lines transduced with herpes simplex virus thymidine kinase. Cancer Gene Ther. 7, 563-573.
59. Rubsam, L. Z., Davidson, L., and Shewach, D. S. (1998) Superior cytotoxicity with gancyclovir compared with acyclovir and 1-β-D- arabinofuranosylthymine in herpes simplex virus-thymidine kinase-expressing- cells: a novel paradigm for cell killing. Cancer Res. 58, 3873-3882.
60. Boucher, P. D., Ostruszka, L. J., and Shewach, D. S. (2000) Synergistic enhancement of herpes simplex virus thymidine kinase/ganciclovir mediated cytotoxicity by hydroxyurea. Cancer Res. 60, 1631-1636.
61. Huang, Z., Raychowdhury, K., and Waxman, D. J. (2000) Impact of liver P450 reductase suppression on cyclophosphamide activation, pharmacokinetics and antitumoral activity in a cytochrom P450-based cancer gene therapy model. Cancer Gene Ther. 7, 1034-1042.
62. Jounaidi, Y. and Waxman, D. J. (2000) Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy. Cancer Res. 60, 3761-3769.
63. Kanyama, H., Tomita, N., Yamano, T., et al. (2001) Usefulness of repeated intratumoral gene transfer using hemagglutinating virus of Japan-liposome method for cytosine deaminase suicide gene therapy. Cancer Res. 61, 14-18.
64. Jounaidi, Y. and Waxman, D. J. (2001) Frequent, moderate dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase based cancer gene therapy. Cancer Res. 61, 4437-4444.
65. Brust, D., Feden, J., Farnsworth, J., Amir, C., Broaddus, W. C., and Valerie, K. (2000) Radiosensitization of rat glioma with bromodeoxycytidine and adenovirus expressing herpes simplex virus-thymidine kinase delivered by slow, rate-controlled positive pressure infusion. Cancer Gene Ther. 7, 778-788.
66. Valerie, K., Brust, D., Farnsworth, J., et al. (2000) Improved radiosensitization of rat glioma cells with adenovirus-expressed mutant herpes simplex virus-thymidine kinase in combination with acyclovir. Cancer Gene Ther. 7, 879-884.
67. Valerie, K., Hawkins, W., Farnsworth, J., et al. (2001) Substantially improved in vivo radiosensitization of rat glioma with mutant HSV-TK and acyclovir. Cancer Gene Ther. 8, 3-8.
68. Kawashita, Y., Ohtsuru, A., Kaneda, Y., et al. (1999) Regression of hepatocelluar carcinoma in vitro and in vivo by radiosensitising suicide gene therapy under the inducible and spatial control of radiation. Hum. Gene Ther. 10, 1509-1519.
69. Nuyts, S., Theys, J., Landuyt, W., Van Mellaert, L., Lambin, P., and Anne, J. (2001) Increasing specificity of anti-tumour therapy: cytotoxic proteins delivery by non-pathogenic Clostridia under regulation of radio-induced promoter. Anticancer Res. 21, 857-862.
70. Nuyts, S., Van Mellaert, L., Theys, J., Landuyt, W., Lambin, P., and Anne, J. (2001) The use of radiation-induced bacterial promoters in anaerobic-conditions: a means to control gene expression in Clostridium-mediated gene therapy. Radiat. Res. 155, 716-723.
71. Steffens, S., Frank, S., Fisher, U., et al. (2000) Enhanced green fluorescent proteinfusion proteins of herpes simplex virus type 1 thymidine kinase and cytochrome P450 4B1: applications for prodrug-activating gene therapy. Cancer Gene Ther. 7, 806-812.
72. Tjuvajev, J.G., Finn, R., Watanabe, K., et al. (1996) Noninvasive imaging of herpes simplex virus thymidine kinase gene transfer and expression: a potential method for monitoring clinical gene therapy. Cancer Res. 56, 4087-4095.
73. Tjuvajev, J.G., Avril, N., Oku, T., et al. (1998) Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. Cancer Res. 58, 4333-4341.
74. Yagoubi, S. S., Wu, L., Liang, Q., et al. (2001) Direct correlation between positron emission tomographic images of two reporter genes delivered by two distinct adenoviral vectors. Gene Ther. 8, 1072-1080.
75. 124/ 125I]FIAU for imaging herpes simplex virus type 1 thymidine kinase gene expression. Eur. J. Nucl. Med 28, 721-729.
76. Huber, B. F., Austin, E. A., Richards, C. A., Davis, S. T., and Good, S. S. (1994) Metabolism of 5-fluorocytidine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc. Natl. Acad. Sci. USA 91, 8302-8306.
77. Imaizumi, K., Hasegawa, Y., Kawabe, T., Emi, N., Saito, H., Naruse, K., and Shimokata, K. (1998) Bystander tumoricidal effect and gap junctional communication in lung cancercells. Am. J. Respir. Cell Mol. Biol. 18, 205-212.
78. Wygoda, M. R., Wilson, M. R., Davis, M. A., Trosko, J. E., Rehemtulla, A., and Lawrence, T. S. (1997) Protection of herpes simplex virus thymidine kinase-transduced cells fromganciclovir-mediated cytotoxicityby bystander cells: the good Samaritan effect. Cancer Res. 57, 1699-1703.
79. Andrade-Rosental, A. F., Rosental, R., Hopperstad, M. D., Wu, J. K., Vrionis, F. D., and Spray, D. C. (2000) Gap junctions: the "kiss of death" and the "kiss of life." Brain Res. Rev. 32, 308-315.
80. Touraine, R. L., Vahanian, N., Ramsey, W. J., and Blaese, R. M. (1998) Enhancement of the herpes simplex virus thymidine kinase/ganciclovir bystander effect and its antitumor efficacy in vivo by pharmacologic manipulation of gap junctions. Hum. Gene Ther. 9, 2385-2391.
81. Touraine, R. L., Ishii-Morita, H., Ramsey, W. J., and Blaese, R. M. (1998) The bystander effect in the HSVtk/ganciclovir system and its relation to gap junctional communication. Gene Ther. 5, 1705-1711.
82. Grignet-Debrus, C., Cool, V., Baudson, N., Velu, T., and Calberg-Bacq, C.-M. (2000) The role of cellular- and prodrug-associated factors in the bystander effect induced by the Varicella zoster and Herpes simplex viral thymidine kinases in suicide gene therapy. Cancer Gene Ther. 7, 1456-1468.
83. Kaneko, Y. and Tsukamoto, A. (1995) Gene therapy of hepatoma: bystander effect s and non-apoptotic cell death induced by thymidine kinase and ganciclovir. Cancer Lett. 96, 105-110.
84. Ramesh, R., Marrogi, A. J., Munshi, A., Abboud, C. N., and Freeman, S. M. (1996) In vivo analysis of the "bystander effect": a cytokine cascade. Exp. Hematol. 24, 829-838.
85. Agard, C., Ligeza, C., Dupas, B., et al. (2001) Immune-dependent distant bystander effect after adenovirus-mediated suicide gene transfer in a rat model of liver colorectal metastasis. Cancer Gene Ther. 8, 128-136.
86. Majumdar, A., Zolotorev, A., Samuel, S., et al. (2000) Efficacy of herpes simplex virus thymidine kinase in combination with cytokine gene therapy in an experimental metastatic breast cancer model. Cancer Gene Ther. 7, 1086-1099.
87. Cao, X., Huang, X., Ju, D.W., Zhang, W.P., Hamada, H., and Wang, J. (2000) Enhanced antitumoral effect of adenovirus-mediated cytosine deaminase gene therapy by induction of antigen-presenting cells through stem cell factor/granulocyte macrophage colony-stimu-lating factor gene transfer. Cancer Gene Ther. 7, 177-186.
88. Rivas, C., Chandler, P., Melo, J. V., Simpson, E., and Apperley, J. F. (2000) Absence of in vitro or in vivo bystander effects in a thymidine kinase-transduced murine T-lymphoma. Cancer Gene Ther. 7, 954-962.
89. Karle, P., Renner, M., Salmons, B., and Gunzburg, W. H. (2001) Necrotic, rather than apoptotic death caused by cytochrome P450-activated ifosfamide. Cancer Gene Ther. 8, 220-230.